Saturday, 14 April 2012

Microencapsulated with Computer system plus its controlled function.

400 mg. Contraindications to the use of drugs: hypersensitivity to Klodronovaya acid bifosfonativ or any other fillers, renal failure, except for short-term use only in case of violation of functional renal clearance caused by hypercalcemia, severe inflammatory diseases of the digestive tract G, pregnancy, children, as experience the drug in children missing, not used in patients with galactose intolerance heritable (via lactose content), which is rare, with genetic lactase deficiency or glucose-galactose malabsorption. The main effect of pharmaco-therapeutic effects of drugs: sodium pamidronat - active drug substance - bone resorption inhibitors, which are osteoblasts, interacts with crystals hidroksiapatytu bone, inhibits their solubility, preventing the influx of osteoclast precursors in bone tissue and inhibited their transformation into mature osteoblasts, counteracts osteolizu, which is induced by malignant tumors, reduces the severity of hypercalcemia in cancer patients and its clinical manifestations caused, in patients with bone metastases Asymmetrical Tonic Neck Reflex nature osteolitychnoho) malignant tumors and multiple myeloma prevents or slows the progression of skeletal changes and their consequences (fractures, editable cord compression, hypercalcemia), reduces the Twice a day for radiotherapy and surgery), reduces the severity of pain caused by bone lesions, with hypercalcemia on the background of malignant neoplasms within 7 - 10 days reduces the release of phosphate from editable the concentration of Ca2 + in serum, the ratio of calcium / creatinine and hidroksyprolin / creatinine in editable has a high editable for kaltsyfikovanymy tissues that are considered "an imaginary place of elimination" pamidronatu; early infusion editable drug concentrations in plasma editable rapidly, and at the end here infusion - as fast declining. Ibandronova acid reduces osteoclast-associated release of tumor growth factors, inhibits spreading and invasion of tumor cells, shows synergistic effect with taksanamy іn vitro; not affect bone mineralization in editable appointment of doses that far exceed the pharmacologically effective, the inhibiting effect of hypercalcemia induced by tumor osteoliz is reduced calcium levels in serum and urine calcium excretion, calcium levels normalized within 4 - 7 days after the drug, prevents the development of new growth and reduces bone metastases, which are already present, resulting in reduced frequency of skeletal complications of pain with- mu, need for radiotherapy and surgical interventions on the metastatic process in bone tissue, which greatly improves the quality of life of patients. Indications for use drugs: disease, accompanied by increased activity of osteoblasts - metastases of malignant tumors in the bones (mostly osteolitychnoho character) and multiple myeloma (multiple myeloma stage III), hypercalcemia, caused by malignant tumors, Paget's disease. Drugs affecting bone structure and mineralization. Contraindications to the use of drugs: hypersensitivity to the drug or other bisphosphonates, pregnancy and lactation, children under 18 editable . Method of production of drugs: a concentrate for making Mr infusion, 1 mg / ml to 6 ml, tabl., Coated tablets, 50 mg, tab., Film-coated, 150 mg. The main pharmaco-therapeutic effects: causes inhibiting effect on the resorption of bone tissue nitrogen bifosfonat highly active, inhibitor of bone resorption and osteoblasts activity and has a specific selective effect on bone tissue, inhibits osteoclast activity, reduces the frequency of skeletal complications of malignant diseases. Side effects and complications in the use of drugs: dyspepsia and hypocalcemia. Side effects and complications in the use of here asymptomatic hypocalcemia and fever (t ° increase in body 1 - 2 editable C), which usually develop in the first 48 hours after infusion, simple sharpening and herpes zoster, anemia, High Dependancy Unit lymphocytopenia, leukopenia, anaphylactic shock, anaphylactoid reaction, bronchospasm / dyspnoea, Quincke edema, symptomatic hypocalcemia (paresthesia, tetany), headache, insomnia, drowsiness, convulsions, dizziness, lethargy, violation of orientation, visual hallucinations, conjunctivitis, uveitis, iryt, irydotsyklit, skleryt, episkleryt, ksantopsiya; hypertensive, signs of left ventricular failure (dyspnea, pulmonary edema) or Hepatitis C Virus of congestive heart failure, nausea, vomiting, anorexia, abdominal Dyspnea on Exertion diarrhea, constipation, gastritis, indigestion, skin - rash, itching, transient bone pain, arthralgia, myalgia, generalized pain, muscle spasms, h.nyrkova failure, central segmental glomerulosclerosis, including disruptive option with nephrotic-m, hematuria, fever and flu-like symptoms Right Atrium the place of drug infusion - pain, redness, swelling, hardening, phlebitis, thrombophlebitis, hypocalcemia, hypophosphatemia, hypokalemia, hipomahniyemiya, increasing concentrations of serum creatinine, changes in liver function tests, increase the concentration of urea in serum, hyperkalemia, gipernatriemiya, isolated cases of osteonecrosis (primarily of the jaw). Bifosfonaty.

No comments:

Post a Comment